Immunic (IMUX) Stock Forecast, Price Target & Predictions

OverviewOwnership Financials Chart Transcripts

IMUX Stock Forecast

Immunic stock forecast is as follows: an average price target of $5.00 (represents a 367.29% upside from IMUX’s last price of $1.07) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

IMUX Price Target

The average price target for Immunic (IMUX) is $5.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 367.29% upside from IMUX's last price of $1.07.

IMUX Analyst Ratings

Buy

According to 6 Wall Street analysts, Immunic's rating consensus is 'Buy'. The analyst rating breakdown for IMUX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immunic Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 21, 2022	Market Perform	Leerink Partners	$5.00	$2.08	139.81%	367.29%

The latest Immunic stock forecast, released on Oct 21, 2022 by Market Perform from Leerink Partners, set a price target of $5.00, which represents a 139.81% increase from the stock price at the time of the forecast ($2.08), and a 367.29% increase from IMUX last price ($1.07).

Immunic Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.07	$1.07	$1.07
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Immunic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunic's last price of $1.07. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 16, 2024	EF Hutton		Buy	Initialise
Sep 04, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 27, 2024	B. Riley		Buy	Initialise
Jul 16, 2024	Piper Sandler	Overweight	Overweight	Hold
Apr 05, 2024	Brookline Capital		Buy	Initialise
Oct 21, 2022	SVB Leerink		Market Perform	Downgrade
Jun 10, 2022	Roth Capital	Buy	Buy	Hold

Immunic's last stock rating was published by EF Hutton on Sep 16, 2024. The company Initialise its IMUX rating from "null" to "Buy".

Immunic Financial Forecast

Immunic Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$470.77M	$452.66M	$452.66M	$434.56M	-	-	-	-	-	-	-	-	-	-	-	-	$6.00K	$6.00K	-
High Forecast	$470.77M	$452.66M	$452.66M	$434.56M	-	-	-	-	-	-	-	-	-	-	-	-	$6.00K	$6.00K	-
Low Forecast	$470.77M	$452.66M	$452.66M	$434.56M	-	-	-	-	-	-	-	-	-	-	-	-	$6.00K	$6.00K	-
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	4	2	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Immunic's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMUX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Immunic EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	4	2	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict IMUX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunic's previous annual EBITDA (undefined) of $NaN.

Immunic Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	4	2	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$150.23M	$146.39M	$148.37M	$143.36M	$-9.48M	$-8.55M	$-7.95M	$-8.38M	$-16.55M	$-15.62M	$-15.33M	$-15.54M	$-21.09M	$-19.86M	$-19.42M	$-22.99M	$-24.16M	$-22.12M	$-23.55M
High Forecast	$150.23M	$146.39M	$148.37M	$143.36M	$-9.48M	$-8.55M	$-7.95M	$-8.38M	$-16.55M	$-15.62M	$-15.33M	$-15.54M	$-21.09M	$-19.86M	$-19.42M	$-20.23M	$-22.15M	$-22.12M	$-23.55M
Low Forecast	$150.23M	$146.39M	$148.37M	$143.36M	$-9.48M	$-8.55M	$-7.95M	$-8.38M	$-16.55M	$-15.62M	$-15.33M	$-15.54M	$-21.09M	$-19.86M	$-19.42M	$-26.66M	$-26.17M	$-22.12M	$-23.55M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Immunic's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMUX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Immunic SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	4	2	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Immunic's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMUX last annual SG&A of $NaN (undefined).

Immunic EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	4	2	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$1.48	$1.45	$1.47	$1.42	$-0.09	$-0.08	$-0.08	$-0.08	$-0.16	$-0.15	$-0.15	$-0.15	$-0.21	$-0.20	$-0.19	$-0.23	$-0.24	$-0.22	$-0.23
High Forecast	$1.48	$1.45	$1.47	$1.42	$-0.09	$-0.08	$-0.08	$-0.08	$-0.16	$-0.15	$-0.15	$-0.15	$-0.21	$-0.20	$-0.19	$-0.20	$-0.22	$-0.22	$-0.23
Low Forecast	$1.48	$1.45	$1.47	$1.42	$-0.09	$-0.08	$-0.08	$-0.08	$-0.16	$-0.15	$-0.15	$-0.15	$-0.21	$-0.20	$-0.19	$-0.26	$-0.26	$-0.22	$-0.23
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Immunic's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMUX previous annual EPS of $NaN (undefined).

Immunic Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
STTK	Shattuck Labs	$1.15	$12.00	943.48%	Hold
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
IMUX	Immunic	$1.09	$5.00	358.72%	Buy
KZR	Kezar Life Sciences	$6.52	$17.50	168.40%	Buy
FHTX	Foghorn Therapeutics	$5.51	$14.00	154.08%	Buy
ERAS	Erasca	$2.63	$6.00	128.14%	Buy
NRIX	Nurix Therapeutics	$21.18	$32.67	54.25%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
KYMR	Kymera Therapeutics	$42.30	$58.60	38.53%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy

IMUX Forecast FAQ

Is Immunic a good buy?

Yes, according to 6 Wall Street analysts, Immunic (IMUX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of IMUX's total ratings.

What is IMUX's price target?

Immunic (IMUX) average price target is $5 with a range of $5 to $5, implying a 367.29% from its last price of $1.07. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immunic stock go up soon?

According to Wall Street analysts' prediction for IMUX stock, the company can go up by 367.29% (from the last price of $1.07 to the average price target of $5), up by 367.29% based on the highest stock price target, and up by 367.29% based on the lowest stock price target.

Can Immunic stock reach $2?

IMUX's average twelve months analyst stock price target of $5 supports the claim that Immunic can reach $2 in the near future.

What are Immunic's analysts' financial forecasts?

Immunic's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.352M (high $-34.352M, low $-34.352M), average SG&A $0 (high $0, low $0), and average EPS is $-0.339 (high $-0.339, low $-0.339). IMUX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $1.81B (high $1.81B, low $1.81B), average EBITDA is $0 (high $0, low $0), average net income is $588.35M (high $588.35M, low $588.35M), average SG&A $0 (high $0, low $0), and average EPS is $5.81 (high $5.81, low $5.81).